clidinium

Trade name: quarzan

Small moleculeapproved

Approved

Sep 1, 1966

LIBRAX® combines in a single capsule formulation the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide. Chlordiazepoxide hydrochloride is a versatile, therapeutic agent of proven value for the relief of anxiety and tension. It is indicated when anxiety, tension or apprehension are significant components of the clinical profile. It is among the safer of the effective psychopharmacologic compounds. Clidinium bromide is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. LIBRAX® is indicated to control emotional and somatic factors in gastrointestinal disorders. It may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. — NCATS

Clinical trial activity

1 trials · 2 clinical orgs · 19 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jun 1, 2002 (NCT00516854)

Timeline

1960s

  1. Jun 1, 1966

    Roche — First NDA Organization

  2. Jun 1, 1966

    Roche — NDA Organization

  3. Sep 1, 1966

    Earliest FDA Approval

  4. Sep 1, 1966

    Bausch Health Companies — Marketing Organization

  5. Sep 1, 1966

    Bausch Health Companies — NDA Secondary Org

2020s

  1. Jul 7, 2020

    Sunrise Medical Research, Inc. — Marketing Organization

  2. Jul 7, 2020

    Nuvo Research Inc. — Marketing Organization

  3. Jul 29, 2020

    Misemer Pharmaceutical — Marketing Organization

  4. Oct 20, 2020

    Chartwell Pharmaceuticals — Marketing Organization

  5. Oct 20, 2020

    Pharma Life Sciences LLC — Marketing Organization

  6. Oct 20, 2020

    Eci Pharmaceuticals Llc — Marketing Organization

  7. Apr 26, 2021

    Alkem Labs Ltd — Marketing Organization

  8. May 10, 2021

    Dr. Reddy's Laboratories — Marketing Organization

  9. Oct 25, 2021

    Amneal Pharmaceuticals — Marketing Organization

  10. Nov 2, 2021

    Teva — Marketing Organization

  11. Jul 19, 2022

    Micro Labs Ltd India — Marketing Organization

  12. Jul 29, 2022

    Corepharma — Marketing Organization

  13. Jul 29, 2022

    Westminster Pharms — Marketing Organization

  14. Sep 14, 2023

    Aurobindo Pharma — Marketing Organization

  15. Sep 15, 2023

    Alembic — Marketing Organization

  16. Dec 14, 2023

    Torrent Pharmaceuticals Limited — Marketing Organization

  17. Jul 8, 2024

    Winder Labs Llc — Marketing Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedSep 1, 1966

Chemistry & pharmacology

Loading structure…

SMILES

C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2
Mol. weight
352.45 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
  • 3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
  • 3-hydroxy-1-methylquinuclidinium benzilate ester
  • 3-hydroxy-1-methylquinuclidinium benzilate ester
  • bromure de clidinium
  • bromure de clidinium
  • bromuro de clidinio
  • bromuro de clidinio
  • clidinii bromidum
  • clidinii bromidum
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium
  • clidinium, 11c-labeled
  • clidinium, 1-(methyl-11c)-labeled
  • clidinium, 3h-labeled
  • clidinium bromid
  • clidinium bromid
  • clidinium bromide
  • clidinium bromide
  • clidinium bromide
  • clidinium bromide
  • clidinium bromide
  • clidinium iodide
  • clidinium iodide, 11c-labeled
  • clidinium iodide, 3h-labeled
  • clidinium iodide, (+-)-isomer
  • n-methyl quinuclidinyl benzilate
  • n-methyl quinuclidinyl benzilate
  • n-methyl quinuclidinyl benzilate
  • quarzan
  • quarzan
  • quarzan
  • quarzan
  • ro-23773
  • ro-23773

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00516854N/AJun 1, 2002Government of Hong Kong, The University of Hong Kong
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of Hong KongGovernment1112002
The University of Hong KongAcademic/Hospital1012002
2 organizations
Page 1 / 1

Marketing (21)

OrganizationOrg typeRelationshipDate
AlembicFor profitMKTGSep 15, 2023
AlembicFor profitSYNSep 15, 2023
Alkem Labs LtdFor profitMKTGApr 26, 2021
Amneal PharmaceuticalsFor profitMKTGOct 25, 2021
Aurobindo PharmaFor profitMKTGSep 14, 2023
Bausch Health CompaniesFor profitMKTGSep 1, 1966
Bausch Health CompaniesFor profitNDA2Sep 1, 1966
Chartwell PharmaceuticalsFor profitMKTGOct 20, 2020
CorepharmaFor profitMKTGJul 29, 2022
Dr. Reddy's LaboratoriesFor profitMKTGMay 10, 2021
Eci Pharmaceuticals LlcFor profitMKTGOct 20, 2020
Micro Labs Ltd IndiaFor profitMKTGJul 19, 2022
Misemer PharmaceuticalFor profitMKTGJul 29, 2020
Nuvo Research Inc.For profitMKTGJul 7, 2020
Pharma Life Sciences LLCFor profitMKTGOct 20, 2020
RocheFor profitNDAJun 1, 1966
Sunrise Medical Research, Inc.For profitMKTGJul 7, 2020
TevaFor profitMKTGNov 2, 2021
Torrent Pharmaceuticals LimitedFor profitMKTGDec 14, 2023
Westminster PharmsFor profitMKTGJul 29, 2022
Winder Labs LlcFor profitMKTGJul 8, 2024